Key Process and Preparation for Thailand IVF to Avoid Genetic Diseases in Children
Opening: Real consultation scenario
Consultation scenario: A 32-year-old woman, a carrier of the beta-thalassemia gene, with a genetically normal husband. She has already given birth to a child carrying the thalassemia gene and hopes her second child will be completely free of the condition. She wants to know if undergoing IVF in Thailand can ensure the baby does not carry any pathogenic genes, the specific process involved, and what the risks are.
Module A: Direct answer to the questionCan PGT technology block the transmission of genetic diseases?
PGT-M (Monogenic disorder screening) can detect known pathogenic loci, allowing the selection of embryos that do not carry specific disease-causing genes for transfer. PGT-SR (Structural rearrangement screening) is used for issues like chromosomal inversions and translocations. PGT-A (Aneuploidy screening) checks for abnormal chromosome numbers. The combined use of these three technologies can block most monogenic disorders and chromosomal structural abnormalities with clearly identified pathogenic genes.
However, it must be clarified: PGT can only detect known genetic diseases with confirmed pathogenic loci. For polygenic disorders (e.g., diabetes, hypertension, schizophrenia) or mitochondrial diseases, current technology cannot screen. Additionally, limitations include embryonic mosaicism, test failure, and inconclusive results.
Why do genetic disease carriers choose Thailand for IVF?
In China, PGT-M requires approval from the hospital's ethics committee, and the types of genetic diseases that can be screened are restricted by policy. Some genetic conditions cannot be performed domestically. Thailand has more flexible policies regarding the application of PGT technology. It allows screening for various monogenic diseases without approval and permits simultaneous PGT-A and PGT-M, improving embryo selection efficiency. Additionally, some Thai reproductive centers have experienced laboratories with specialized protocols for ovulation induction and embryo culture for genetic disease carriers.
However, choosing Thailand is not without prerequisites: Genetic counseling and genetic testing must be completed in China, with reports issued in both Chinese and English. Thai doctors will evaluate the reports to determine suitability for PGT-M and the required testing strategy.
Module I: Actual processActual process and timeline
A complete cycle takes approximately 3‑4 months, divided into two phases: preparation in China and treatment in Thailand.
Phase 1: Preparation in China (1‑2 months)
- Genetic counseling: Confirm the type of genetic disease, inheritance pattern, and pathogenic gene loci. Family members' (parents, children) genetic samples are needed for pedigree verification.
- Genetic testing: Complete whole exome sequencing or targeted gene sequencing at a qualified laboratory to identify the pathogenic loci. The test report must be bilingual (Chinese and English).
- Fertility assessment: Female: check AMH, FSH, LH, antral follicle count. Male: semen analysis, chromosome karyotype.
- Document preparation: Passport (valid for at least 6 months), notarized marriage certificate, previous medical records.
Phase 2: Treatment in Thailand (approximately 25‑30 days)
| Stage | Time | Main Activities |
|---|---|---|
| Clinic registration & file creation | Day 1‑2 | Meet doctor, review reports, create file, female ultrasound + blood test |
| Ovarian stimulation | Day 3‑14 | Daily gonadotropin injections, follicle + hormone monitoring every 2‑3 days |
| Egg retrieval surgery | Day 15‑16 | Egg retrieval 36 hours after trigger shot, simultaneous sperm collection |
| Embryo culture + biopsy | Day 17‑22 | Blastocyst culture for 5‑6 days, trophectoderm cell biopsy |
| PGT testing | Day 23‑42 | Sample sent for testing, results in about 2‑4 weeks (wait for report back home) |
| Frozen embryo transfer | Next menstrual cycle | Endometrial preparation followed by transfer of normal embryo, pregnancy test 12 days after transfer |
Note: Specific timelines may vary by 1‑3 days depending on follicle development speed and laboratory schedule.
Module L: Interpretation of key indicatorsInterpretation of key examination indicators
| Item | Normal Range | Significance for Genetic Disease IVF |
|---|---|---|
| AMH | 2.0‑6.8 ng/mL | Reflects egg reserve. Below 1.5 indicates diminished reserve, potentially affecting the number of embryos available for biopsy. |
| Basal FSH | 5‑10 IU/L | Levels >10 suggest reduced ovarian function, requiring adjusted stimulation protocol. |
| Antral Follicle Count (AFC) | 8‑15 | Total number of follicles in both ovaries, directly related to the number of eggs retrieved. |
| Chromosome Karyotype | 46,XX / 46,XY | Rules out chromosomal structural abnormalities in both partners, preventing unbalanced rearrangements in embryos. |
| Pathogenic Gene Sequencing | Identified pathogenic loci | Foundation for PGT-M testing; the pathogenic gene and inheritance pattern must be confirmed. |
| Pedigree Verification | Co-segregation analysis | Requires genetic samples from the patient's parents or children to verify co-segregation of the pathogenic locus with the disease. |
Note: The above indicators must be interpreted jointly by a reproductive doctor and a genetic counselor. An abnormal single indicator does not preclude PGT, but it may affect protocol design and success rates.
Module G: Most easily overlooked detailsMost easily overlooked details
- Genetic report language: Thai doctors require genetic test reports in English. Some domestic institutions only provide reports in Chinese. Confirm in advance whether a bilingual report can be issued, or arrange for translation and notarization by a certified agency.
- Family sample collection: Many genetic diseases require genetic samples from the patient's parents or children for pedigree verification. If parents are deceased or refuse to provide samples, it may be impossible to confirm the pathogenic locus, making PGT-M unfeasible.
- Passport validity: Thailand requires a passport valid for at least 6 months. Check before planning your trip; renew it if it is expired or has less than 6 months validity.
- Translation of previous medical records: Domestic surgical records, hysteroscopy reports, etc., need to be translated into English and stamped. Thai hospitals accept translations from professional translation companies.
- Confirmation of genetic disease type: Not all genetic diseases are suitable for PGT-M. For example, mitochondrial diseases, polygenic disorders, and certain imprinting disorders cannot be screened with current technology.
Common pitfalls
① Believing PGT can screen for all genetic diseases. In reality, it can only detect monogenic disorders with known pathogenic genes and chromosomal structural abnormalities. Polygenic diseases, de novo mutations, and mosaicism cannot be guaranteed.
② Ignoring the risk of embryonic mosaicism. A biopsy takes 5‑10 trophectoderm cells, which may not represent all cells in the embryo. A mosaic embryo might show normal results but still carry a risk of abnormality after transfer.
③ Insufficient qualifications of genetic testing institutions. Some small laboratories may have insufficient sequencing depth or weak analytical capabilities, leading to missed detection or misjudgment of pathogenic loci. It is advisable to choose large, qualified third-party testing institutions with genetic counseling accreditation.
④ Ovarian stimulation protocol unsuitable for genetic disease carriers. Certain genetic conditions (e.g., Fragile X syndrome) are associated with diminished ovarian function, requiring individualized stimulation protocols. Inexperienced doctors may overlook this.
⑤ Focusing only on female examinations, neglecting the male partner. Even if the male's genes are normal, abnormal chromosome karyotypes can cause embryonic chromosomal issues. Both partners require complete evaluation.
Module C: Doctor's perspectiveHow doctors view genetic disease carriers going to Thailand for IVF
Genetic counseling doctors emphasize: Pedigree genetic analysis must be completed first to confirm the pathogenic gene locus and assess the inheritance pattern (dominant/recessive/X-linked) before determining the feasibility of PGT-M. Some genetic diseases exhibit genetic heterogeneity, requiring combined verification using multiple testing methods.
Reproductive doctors focus on: Ovarian reserve and embryo culture efficiency. PGT‑M requires culturing embryos to the blastocyst stage and performing a biopsy, which demands high embryo quality. Patients with diminished ovarian function may have fewer eggs retrieved, potentially resulting in insufficient embryos for testing. Such individuals are advised to undergo ovarian function optimization 3‑6 months in advance, or consider egg donation combined with PGT.
Thai doctors generally recommend: Obtain a recording or written confirmation of genetic counseling before transfer to understand the limitations and failure risks of PGT. Some centers require signing a specific PGT informed consent form covering test accuracy, mosaicism probability, and contingency plans in case of failure.
Module E: Differences between countriesDifferences in genetic disease screening across countries
| Country/Region | PGT Policy | Screenable Genetic Diseases | Approximate Cost (CNY) |
|---|---|---|---|
| China | Requires hospital ethics approval, disease restrictions | Approximately 200‑300 types (subject to approval) | 80,000‑150,000 (including PGT) |
| Thailand | No approval needed, flexible disease scope | 600+ types (customizable) | 120,000‑200,000 (including PGT) |
| USA | No approval, most mature technology | 800+ types (whole genome screening) | 250,000‑400,000 (including PGT) |
| Cambodia | Loose policy, but variable clinic quality | Some common diseases | 80,000‑150,000 (including PGT) |
Recommendation: Thailand offers a balance between cost-effectiveness and disease coverage, making it suitable for most families with genetic disease carriers. However, if the genetic condition is very rare or requires whole genome screening, the USA might be more appropriate. If domestic policy allows and the disease is on the approved list, China is also a viable option.
Ending: Risk reminder• PGT‑M test failure rate is approximately 2%‑5%, potentially due to DNA amplification failure or inconclusive results.
• Probability of embryonic mosaicism is about 3%‑5%; a normal test result does not entirely rule out a low percentage of abnormal cells after transfer.
• Ovarian stimulation and egg retrieval carry risks of ovarian hyperstimulation syndrome, infection, and bleeding, with an incidence of about 1%‑3%.
• Even with transfer of a normal embryo, there are still obstetric risks such as miscarriage and fetal abnormalities, similar to natural pregnancy rates.
• Medical dispute resolution mechanisms in Thailand differ from those in China. It is advisable to choose a reputable reproductive center and keep all medical records.
Recommendation: Before deciding to go to Thailand, complete comprehensive genetic counseling and genetic testing in China to confirm the pathogenic gene is clearly identified and PGT‑M is feasible. Bring all reports to Thailand to avoid cycle cancellation or test failure due to inadequate preparation.
Quick FAQ: When should overseas IVF tests be done? It is recommended to complete genetic counseling and genetic testing 3‑6 months in advance. How long in advance should one prepare for overseas IVF? At least 3 months. What is the passport validity requirement for overseas IVF? More than 6 months. Can I still do overseas IVF with low AMH? Yes, but an individualized stimulation protocol is needed, and the number of eggs retrieved may be lower. What preparations are needed for advanced maternal age overseas IVF? Additional ovarian function assessment, hysteroscopy, and genetic counseling. Is preconditioning needed before overseas IVF? It is recommended to supplement folic acid and vitamin D, control weight, and improve egg and sperm quality.
